-
Ozempic and eye conditions: Ophthalmologists weigh in
A week after a study connected Ozempic and Wegovy to an eye condition that can cause partial blindness, two ophthalmology organizations said they have "been aware of other vision changes for some time." -
Ozempic vs. Mounjaro: Which fared better in 1st large study
Using Mounjaro for one year led to more weight loss than Ozempic did in a study of 18,386 patients, according to the results published July 8 in JAMA Internal Medicine. -
Ozempic may lower risk for certain cancers: New research
GLP-1 drugs such as Ozempic and Wegovy may lower the risk of developing certain obesity-related cancers, according to a new study from researchers at Case Western Reserve University in Cleveland. -
Ozempic linked to rare condition that causes blindness, study suggests
A new study suggests patients taking semaglutide — the active ingredient in Ozempic and Wegovy — may be at higher risk of an eye condition that can cause blindness. However, study authors and experts told NBC News the findings only show an association, and that additional research is needed to confirm a causal link. -
How NYU Langone's bariatric surgery chief is thinking about the first GLP-1 generic
The world of GLP-1s is quickly evolving with new clinical research, insurance coverage decisions, and emerging products on the market. -
Biden, Sanders to Ozempic maker: 'Stop ripping off' Americans
President Joe Biden, who has challenged the pharmaceutical industry for decades, joined Sen. Bernie Sanders' clash with Novo Nordisk in a July 2 op-ed published in USA Today. -
The GLP-1 coverage dilemma for employers
Big costs require big decisions, as illustrated by how GLP-1s are causing leaders of hospital employee health plans to rethink their coverage plans. -
GLP-1s are reshaping plastic surgery patient demands
GLP-1s, the new blockbuster drug class, has taken off in popularity as a powerful treatment for patients with obesity and Type 2 diabetes, but they've driven a drastic increase in plastic surgery procedures, too, Bloomberg reported June 25. -
'The era of the GLP-1': Obesity drugs' next play
Healthcare is in its GLP-1 era. Following Novo Nordisk's blockbuster success with Ozempic and Wegovy, many drugmakers are focused on developing new iterations of weight loss drugs that could come with fewer side effects and drive down costs. -
11 updates on GLP-1s
The prevalence of face-lifts increased 8% between 2022 and 2023, a growth that the American Society of Plastic Surgeons links to Ozempic and Wegovy, according to a June 25 report from the organization. -
Novo Nordisk eyes another Ozempic approval by January
By January 2025, Type 2 diabetes therapy Ozempic might be FDA approved for kidney disease-related events. -
Teva launches first generic GLP-1
Teva Pharmaceuticals is launching the first authorized generic of Victoza, the first generic GLP-1 product available in the United States. -
GLP-1s effective at pediatric weight management, BMI reduction
GLP-1s, specifically semaglutide, had the largest effect on decreasing body mass index and maintaining weight management in children, according to a study published June 18 in JAMA Network. -
Physicians tout 'obesity first' approach with weight loss drugs
Many physicians in obesity medicine have observed a trend among their patients: Those with obesity begin taking a weight loss drug like Wegovy, and their other chronic conditions improve or clear up entirely. -
How Amazon Pharmacy is thinking about 'the messy state' of weight loss drugs
Weight loss drugs were one of the most talked about topics at AHIP's June 2024 conference in Las Vegas, especially with the Amazon Pharmacy team. -
Are weight loss drugs curbing alcohol, gambling addictions? 3 physician execs weigh in
Anecdotally, some people taking GLP-1s report having less cravings for more than just food. -
Sanders calls vote to subpoena Novo Nordisk president
Following jousts between Vermont Sen. Bernie Sanders and Novo Nordisk, the Senate Committee on Health, Education, Labor, and Pensions will vote June 18 on whether to subpoena the drugmaker's president about the cost of Ozempic and Wegovy. -
Kroger Health to offer GLP-1s at in-store clinics
Kroger Health's in-store clinics are revamping the company's weight management program to include prescriptions for GLP-1s such as Wegovy and Zepbound. -
Weight loss drugs don't pose severe risks to surgery, study finds
Gastric emptying is a critical component to most perioperative care instructions. Now with GLP-1 medications slowing gastric emptying purposefully, researchers are racing to understand how and if the new class of drugs affects surgical procedures. -
Novo Nordisk races to boost Ozempic, Wegovy production
There are only two places in the world where semaglutide (Ozempic and Wegovy) is made, and Novo Nordisk is racing against time and high demand to increase supply, Bloomberg reported May 30.
Page 1 of 50